Severe COPD and biologic therapy explained

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that causes airflow limitation, persistent breathing difficulty, chronic cough with sputum production, and (for many patients) frequent exacerbations (sudden worsening episodes). Severe COPD substantially limits daily activities, and frequent exacerbations are associated with progressive decline in lung function and elevated mortality risk.

The foundational therapy. The mainstay of COPD management is inhaler therapy with bronchodilators (medicines that open up the airways) and (for many patients) inhaled corticosteroids. Modern triple therapy combines a long-acting beta-agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid in a single inhaler. Combined with smoking cessation, pulmonary rehabilitation, vaccinations, and oxygen as needed, this is the standard of care for symptomatic COPD.

The exacerbation problem. Some COPD patients continue to have frequent exacerbations despite optimal inhaler therapy. Each exacerbation can require oral corticosteroids, antibiotics, and sometimes hospitalisation; over time, exacerbations contribute to faster lung function decline and worsening quality of life.

The traditional add-on options for frequent exacerbators. Chronic macrolide therapy (azithromycin) reduces exacerbation frequency in many patients. Roflumilast is an oral PDE4 inhibitor option in selected patients with chronic bronchitis phenotype.

The new biologic option. For some patients with severe COPD and frequent exacerbations, the underlying biology involves type-2 inflammation (the same kind of inflammation that drives severe asthma, atopic dermatitis, and other allergic-pathway conditions). These patients often have an elevated blood eosinophil count, a clue that points toward type-2 inflammation as a driver.

Dupilumab is an antibody that blocks IL-4 and IL-13 signalling, two key drivers of type-2 inflammation. Dupilumab now carries COPD approval for patients with eosinophilic phenotype and persistent exacerbations on optimal inhaler therapy. It is given as a subcutaneous injection every 2 weeks. In trials, dupilumab substantially reduced exacerbations in this patient subset.

Follow-on biologics: mepolizumab and benralizumab (anti-IL-5-pathway medicines) have reported pivotal data in COPD eosinophilic phenotype.

Another emerging option. Ensifentrine is an inhaled medicine that combines two mechanisms (PDE3 and PDE4 inhibition) in a single agent, adding bronchodilator and anti-inflammatory effects on top of standard inhaler therapy. It is approved for COPD maintenance.

The biomarker pathway. The biologic option only makes sense for patients with the appropriate type-2 inflammatory phenotype, identified through blood eosinophil count and clinical features. Sponsors and clinicians benefit from structured biomarker-pathway integration into severe COPD care.

What to expect. Severe COPD therapy is becoming more individualised, with biomarker-defined phenotypes guiding therapy selection. For patients with eosinophilic phenotype and frequent exacerbations despite optimal inhaler therapy, biologic therapy can substantially reduce exacerbation frequency. For patients without that phenotype, optimised inhaler therapy plus other add-on options (chronic macrolide, ensifentrine, roflumilast in selected patients) remain the foundation. Discussion with a pulmonologist about biomarker-defined phenotype is the modern approach to severe COPD that has not responded to standard therapy.